IsraCann...
Geschäftsbericht
5. Oktober 2020
1. Geben Sie einen allgemeinen Überblick und diskutieren Sie die Entwicklung des Geschäfts und der Geschäftstätigkeit der Emittentin im letzten Monat. Wenn die Emittentin inaktiv war, geben Sie diese Tatsache an.
- Das Unternehmen arbeitet weiterhin an behördlichen Genehmigungen für sein Nir Yisrael-Projekt. Die Anträge des Abwicklungsbeauftragten werden umgesetzt und ein überarbeiteter Antrag wird vorbereitet.
- Das Unternehmen macht mit seinem Joint-Venture-Partner weitere Fortschritte bei der Fertigstellung der Anlage in Ein Hahoresh.
2. Geben Sie einen allgemeinen Überblick und diskutieren Sie die Aktivitäten des Managements.
Bitte beachten Sie Punkt 1
3. Beschreiben und liefern Sie Details zu neuen Produkten oder Dienstleistungen, die entwickelt oder angeboten werden. Geben Sie für Rohstoffunternehmen Einzelheiten zu neuen Bohr-, Explorations- oder Produktionsprogrammen und zum Erwerb neuer Liegenschaften an und fügen Sie alle nach dem Wertpapiergesetz von Ontario erforderlichen Mineral-, Öl- und Gas- oder sonstigen Berichte bei.
Bitte beachten Sie Punkt 1.
4. Beschreiben und liefern Sie Details zu Produkten oder Dienstleistungen, die eingestellt wurden. Geben Sie für Rohstoffunternehmen Einzelheiten zu Bohr-, Explorations- oder Produktionsprogrammen an, die geändert oder aufgegeben wurden.
Keiner.
14 OCT 2020 / CORPORATE NEWS
Legal Exports Poised to Drive Domestic Industry Growth
VANCOUVER, BC, — (GLOBE NEWSWIRE – October 14, 2020) – Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer is pleased to announce that the government of Israel has officially enacted the legislation for the export of medical cannabis, clearing the way for sales abroad that the government expects could generate more than 1 billion shekels ($273 million) in annual revenue.
Economy Minister Eli Cohen gave final approval for the exports more than a year after the cabinet initially supported the legislation. Within Israel, medical use of cannabis is permitted with recreational use largely decriminalised. The ministry reports about 70,000 Israelis currently use medical cannabis consuming an estimated 25 tonnes per year. If this growth trend continues, Israel could see a market of over 200,000 medical patients consuming 85 tonnes per year within the next two years.
14. OKT 2020 / CORPORATE NEWS
Legale Exporte stehen vor dem Wachstum der heimischen Industrie
VANCOUVER, BC, - (GLOBE NEWSWIRE - 14. Oktober 2020) - Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (das „Unternehmen“ oder „Isracann“) mit Sitz in Israel Als hochqualitativer Cannabisproduzent wird bekannt, dass die israelische Regierung die Gesetzgebung für den Export von medizinischem Cannabis offiziell erlassen hat, um den Weg für Verkäufe ins Ausland freizumachen, von denen die Regierung erwartet, dass sie mehr als 1 Milliarde Schekel erzeugen könnten ( 273 Mio. USD) Jahresumsatz.
Wirtschaftsminister Eli Cohen erteilte die endgültige Genehmigung der Exporte mehr als ein Jahr, nachdem das Kabinett die Gesetzgebung ursprünglich unterstützt hatte. Innerhalb Israels ist die medizinische Verwendung von Cannabis gestattet, wobei der Freizeitgebrauch weitgehend entkriminalisiert ist. Das Ministerium berichtet, dass derzeit etwa 70.000 Israelis medizinisches Cannabis konsumieren, das schätzungsweise 25 Tonnen pro Jahr konsumiert. Wenn sich dieser Wachstumstrend fortsetzt, könnte Israel in den nächsten zwei Jahren einen Markt von über 200.000 medizinischen Patienten sehen, die 85 Tonnen pro Jahr verbrauchen."...."...............
19 JAN 2021 / CORPORATE NEWS
Activities in 2020 laid groundwork towards accelerated results
VANCOUVER, BC, — ( January 19, 2021) – Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer is pleased to provide a year end summary of activities and outlook for 2021.
There is a sense of relief that 2020 is now behind us. Over the course of the past year, the impact of COVID-19 has been felt around the globe and will undoubtedly continue to impact countless lives and entire economies for years to come. While many difficulties remain before us all, a guarded optimism is growing daily. The challenges that directly impacted our venture were principally logistical and operational in nature and affected most of the sector equally. Given the Israeli governments increasingly pragmatic outlook regarding cannabis we remain extremely optimistic regarding our ability to achieve our strategic goals for the new year.
In consideration of the disruptive nature of the pandemic, Isracann is nonetheless extremely pleased to have made continued progress at both its domestic operations. At our early-stage Nir, Israel farm, the Company was required to realign elements of its submission to the Settlement Commissioner for the Nir region, which was expedited via the invaluable aid of our regional consultants. This process has paved the way for a formal application to the Ministry of Health. In all other respects the project is poised for fast-tracked completion with commencement of operations to occur as soon as approval is received.
The agreement and commitment to accelerate the completion of the flagship Hefer Valley-based Ein Hahoresh Farm has proven to be a key driver for the Company. With 165,000 sq. ft. of greenhouse canopy and extensive processing capability in-place, the Company and its regional partners are moving rapidly towards industrial-scale operations capable of servicing both the domestic and increasingly important European export markets in 2021.
Per recently amended regulations that require all physical facilities to be completed and approved prior to planting, the construction activities at the Ein Hahoresh farm expanded the onsite post-harvest facility in preparation for commencement of operations and increased demand from growing domestic and export markets. We are well poised to, in the short term, complete the facility and receive the required Security and Ministry of Health approvals to acquire our farm operating license and start planting. Consequently, Isracann and its local consultants are currently scheduling the commencement of planting in March to coincide with the start of optimal climatic conditions. Additionally, applications for certification of Isracann as foreign cannabis cultivation license owners were submitted to the Ministries of Security and Health, which upon acceptance, will result in Isracann’s ability to formally complete any remaining aspects of our joint venture acquisition.
While completion of our farms is the primary focus of the company, we have been actively initiating and expanding our visibility and relationships across the region and onwards into Europe. Our goal has been to establish infrastructural agreements aimed at launching Isracann onto the world stage as a truly international cannabis enterprise. As these pending activities are commercial in nature, and include multiple parties, we look forward to announcing further details outlining our expanded strategic outlook for the coming year as soon as possible.
Concurrently, the domestic legislative, regulatory, and societal environment regarding cannabis production, processing, distribution, and sales within Israel continues to improve as do the opportunities for export operations. Last year saw several landmark rulings and accelerated momentum that is rapidly transforming this emerging sector into a respected national industry.
It is also worth mentioning that Israel has been noted as an early leader in the distribution of coronavirus vaccinations, and this appears to be driving optimism for the entire business community throughout the region. Isracann and its team of professional consultants are confident this will aid initial sales projections upon entry into a domestic marketplace which is markedly more robust than ever before.
Company CEO Darryl Jones comments, “Since our decision to enter the market sector in Israel just 20 short months ago, we have seen cannabis reform, including major advances in legalization, production and distribution. We’ve also seen the door opening up for export sales, and a wholesale shift in cultural acceptance. And yet we have had to deal with some setbacks as the regional governments come to terms with new regulations and the impact of a global pandemic. But one thing to remember is that this is just the playing field, and it is the same field for everyone in the sector. As players, we have engaged top industry professionals to consult on our behalf, incorporated leading agronomic experts to show us the true path to product excellence, and ensured our leadership includes a strong mix of business and production expertise. We have a team with big league knowhow and home field advantage, and this all translates into ability and confidence. We are well positioned and well financed and are committed to ensuring that 2021 is the year Isracann gets fully into the game and starts to deliver the returns we know its capable of. With that vision firmly in-place, we thank all our supporters for your continued trust as we forge ahead to make this year an outstanding opportunity for value creation through the intelligent application of capital into predictably growth-focused areas of the global cannabis industry.”
Ob Isracann das Potential hat Richtung 10€ ??
https://finance.yahoo.com/news/...rt-canadian-cannabis-140000164.html
meine Meinung.... halten und wer mag Kaufen!!!! Kaufen..... ,!, der Markt ist vorhanden und das Wetter in Israel ideal....... für Gras ...
Gruß
Und Israel haben schon lange Erfahrung und forschen.....mit und am Gras ......
Gruß